LABS — Life Science Reit Cashflow Statement
0.000.00%
Last trade - 00:00
- £139.30m
- £232.88m
- £19.94m
- 34
- 52
- 25
- 27
2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|
Period Length: | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS |
Status: | Final | Final | Final |
Net Income/Starting Line | 7.73 | -26.9 | -14.6 |
Non-Cash Items | -8.12 | 31.3 | 23.2 |
Other Non-Cash Items | |||
Changes in Working Capital | 3.92 | -5.46 | -0.961 |
Change in Accounts Receivable | |||
Change in Payable / Accrued Expenses | |||
Cash from Operating Activities | 3.54 | -1.09 | 7.62 |
Capital Expenditures | — | -7.64 | -24 |
Purchase of Fixed Assets | |||
Other Investing Cash Flow Items | -182 | -179 | 12.4 |
Sale/Maturity of Investment | |||
Purchase of Investments | |||
Other Investing Cash Flow | |||
Cash from Investing Activities | -182 | -186 | -11.6 |
Financing Cash Flow Items | -6.06 | -4.39 | -10.5 |
Other Financing Cash Flow | |||
Total Cash Dividends Paid | |||
Net Issuance / Retirement of Stock | |||
Net Issuance / Retirement of Debt | |||
Cash from Financing Activities | 344 | 67.1 | -27.2 |
Beginning Cash Balance | |||
Ending Cash Balance | |||
Net Change in Cash | 166 | -120 | -31.3 |